| Literature DB >> 30907734 |
Michelle Helena Van Velthoven1, Carlos Cordon2.
Abstract
BACKGROUND: There are various complex reasons that influence sustainable adoption of innovations in health care systems. Low adoption can be caused by a lack of support from one or more stakeholders because their needs and expectations are not always considered or aligned.Entities:
Keywords: adoption; digital health; stakeholders; telemedicine
Mesh:
Year: 2019 PMID: 30907734 PMCID: PMC6452285 DOI: 10.2196/11922
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Workshop participants’ background.
| Participant number | Stakeholder and position, and background |
| 1 | University hospital: medical director |
| 2 | University hospital: head of electronic health domain |
| 3 | Patient representative: medical writer background |
| 4 | Patient representative: insurance consultant background |
| 5 | Patient representative: caretaker background |
| 6 | Academic: health sciences researcher |
| 7 | Pharmaceutical company: consumer health director |
| 8 | Pharmaceutical/technological company: computer engineer lead |
| 9 | Private equity: health investor specialist |
| 10 | Health insurance company: senior project manager |
| 11 | Pharmaceutical retail: specialist |
| 12 | Business: digital transformation specialist |
Key facilitators, barriers, and success factors for digital health adoption.
| Facilitators | Barriers | Success factors |
| Priority: Digital health is a priority to improve the quality of health services in Switzerland; politicians are educated on the importance and issues related to digitization | Decentralization and lack of interoperability: Switzerland has 26 cantons and different health laws; there is no common interface for electronic patient record interoperability. Furthermore, there are 4 different languages used (French, German, Italian, and Romansh) | Context clarification: There is a need to put national regulation in place for security, privacy, and “hacking” of digital health innovations (medical devices) |
| High-income country: Large investments are being made in innovation; furthermore, most people are educated and have personal technologies such as smartphones | Lack of long-term planning: People can change health insurance every year, which limits long-term investment of insurance companies | Responsibilities clarification: The responsibilities of different stakeholders need to be clarified, for example, who pays which costs |
| Size: Switzerland is a small country where people know each other | Experience: There is relatively limited experience within Switzerland | Import: Switzerland could make better use of the considerable number of expats bringing in their expertise |
| Culture of innovation: Switzerland has a thriving start-up, and health companies’ “valley” and local initiatives are trialed. Many initiatives over the past two decades have taken place, including the establishment of pharma companies | High health care costs: The overuse of health care is insufficiently limited. Patients pay high insurance and in return want high-quality services. There is a lack of willingness to pay for digital health | Value proposition clarification: The benefits and impact on costs for citizens, for example, fees for services, need to be clarified |
| Consensus: Swiss people like to solve problems together with all stakeholders and common agreement. Opportunities to share data are provided | Low agility: There is a general lack of willingness to share personal data. Rigid and slow adoption of innovation, for example, a paper billing system (“System de Tarification”) | Change enablement: Change processes need to be better enabled to achieve an appropriate proportion of people using a digital health innovation |
Aligned and conflicting interests of stakeholders.
| Stakeholders, aligned interests | Conflicting interests | |
| The possibility to access more targeted data to be used in the development of drugs | The possibility of being left behind when data are not shared | |
| Potentially increased customer satisfaction | Patients could become more demanding, which could result in the need to change culture and processes | |
| Increased efficiency in the use of resources, for example, by increased compliance of patients taking drugs | A potential reduction in drug sales, for example, by paying per pill versus paying per box of pills, which improves the accuracy of drugs dispensing | |
| Increase in rare disease research and development on the basis of gains from other disease areas | Costs could be escalating by investment in digital health with uncertain returns | |
| Saving staff time and lowering costs | Uncertainty about who pays for what time | |
| Better collaboration with colleagues, for example, by opportunities for information sharing | Health workers could be losing some of their autonomy, for example, by more traceable work by tracking what a staff member is doing | |
| The opportunity to contribute feedback to research and development, for example, postmarket feedback on adverse effects of drugs | Threats to privacy, for example, it being uncertain what happens to personal data | |
| An increased efficiency in treatment, for example, reduced time in the hospital | Challenges for balancing expensive treatment versus the cost to society. It might be the right decision to pay for expensive treatment if the patient can return to society sooner | |
| Expert high-quality care for patients | Private versus mandatory insurance, for example, risk selection on the basis of available personal data. Even though legally this is not possible, it is happening unofficially | |
Facilitators and barriers toward developing safe, high-quality, and usability innovations.
| Facilitators | Barriers |
| Agile approaches can be used to develop digital health innovations | Pharmaceutical companies are not used to using agile approaches |
| A sufficient mass of secure data, for example, use of data for individualization of treatment | People do not want to share data and are concerned about data ownership |
| The government is seen as credible and could use this to, for example, define what a medical device is and support the establishment of standards for safety | Companies developing digital health innovations are not always seen as credible |
| Patient-facing interventions should be focused on patients, which can be achieved by, for example, involving them throughout the development process | Lack of understanding what patient-centeredness really means through studies on patient involvement |
| Clinicians would like to be involved | Clinicians’ role for involvement needs to be defined |
| Interventions need to have shared benefits and measurable outcomes | There are concerns about how to measure cost-effectiveness |
| There is a need for more jobs in digital health | People are concerned about job losses |
| Insurers need to be transparent about their willingness to pay for digital health innovations | People are able to change their health care insurance |